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Sunday, February 3, 2013 153aPatients in heart failure are sometimes implanted with a left ventricular assist
device (LVAD) to bridge them to transplant. Clinical data shows that ~15%
of these patients recover pump function and can subsequently have their
LVAD removed. The goal of our study was to determine whether cellular level
maximal power output of the left ventricle improves after patients are fitted
with LVADs. Myocardial samples were obtained (1) from the left ventricle
apex of patients when they were implanted with a LVAD and (2) from the
left ventricle free wall when they subsequently received a heart transplant.
Non failing cardiac samples were also obtained from organ donors for compar-
ison. All samples were snap frozen in liquid nitrogen and stored in the vapor
phase of liquid nitrogen. Multicellular preparations were then obtained by
chemically permeabilizing the samples in 1% Triton solution after mechanical
homogenization. These preparations were connected between a force trans-
ducer and a motor and maximally activated in a saturating Ca2þ solution.
Once force had reached steady state, the preparations were allowed to shorten
against pre-set loads imposed using SLControl software. Maximum power out-
put was determined from the force-velocity curves. Preliminary results suggest
that LVAD treatment improved cellular level maximum power output and
isometric force. There was also a trend towards a lower maximum shortening
velocity post-LVAD. Further studies, will determine whether intrinsic ventric-
ular function is improved by LVAD implantation as well as the molecular
mechanisms that may mediate any observed responses.
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Omecamtiv mecarbil (OM), a small-molecule increases cardiac contractility by
directly activating cardiac myosin by accelerating phosphate (Pi) release (Ma-
lik et al., 2011). Here we analyzed the affect of OM on the mechanochemical
cycle and motility of human b-cardiac heavymeromyosin expressed in a adeno-
viral/C2C12 muscle cell based system, and purified porcine ventricular myosin
(PV-HMM). Double-mixing stopped-flow fluorescence and phosphate binding
protein (MDCC-PBP) were used to determine the maximum rate (kmax) of
phosphate release. Rates of 30s1 and 35s1 were obtained for human and
porcine cardiac HMM respectively. Addition of 20 mM OM resulted in a
2-fold increase in the maximal rate of actin activated Pi release to kmax =
70 s1 (AM-ADP-Pi _> AM-ADP þ Pi) for both human and porcine cardiac
HMM. The unloaded actin filament velocity measured in the in vitro motility
assay was 0.76 5 0.37 mm/sec for human b-cardiac HMM and 0.97 5 0.23
mm/sec for PV-HMM. OM has two effects on the motor activity: 1) The actin
filament velocity was significantly slower (~ 16 -fold at saturation); 2) the fil-
ament motion became more persistent with long periods of uninterrupted
movement. This suggests that OM recruits more crossbridges to participate
in the movement of the actin filaments resulting in higher forces per filament,
which overcomes the pinning defects that invariably trap actin filaments in nor-
mal motility assays. The increase in attached crossbridges/filament also slows
the filament velocity. The motility data are consistent with the kinetic analysis
indicating that OM accelerates Pi release without dramatically enhancing the
rate of the ATPase hydrolysis. This produces a higher duty ratio in which the
motor spends more of the ATPase cycle in tight binding states. Supported by
AHA-BGIA to EF and AHA-GI to DAW.
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After myocardial infarction, adjacent to the infarct there is a poorly contracting
non-ischemic border zone. The mechanism of border zone dysfunction is un-
clear. We found that border zone dysfunction does not involve myocardial
fibrosis, or a decreased content of either myofibrils or myosin, suggesting there
is a defect in the contractile mechanism. Goal: Determine the mechanism for
border zone dysfunction. Methods: We used sheep hearts 2 weeks after
apical infarction. Cardiac muscle strips were dissected from the border zone
adjacent to the infarct and from a zone remote from the infarct. Myofilament
contraction was assessed using in-vitro isometric and isotonic contractions of
demembranated cardiac muscle strips bathed in activating solutions. To assess
strongly bound cross-bridge formation, we measured muscle stiffness using
high frequency, low amplitude oscillations of muscle length in the absenceof ATP (in this rigor state, cross bridge formation should be maximal).
Results: In border zone myocardium, maximal force development (Fmax)
was reduced by 3152% (n=6, P<0.01) compared to Fmax of remote zone
myocardium (8551 mN/mm2). The stiffness in the rigor state was reduced
by 3456% (n=5, P<0.05) in border zone myocardium versus remote zone
myocardium, suggesting impaired cross bridge formation in the border zone.
There was no difference between border zone and remote zone myocardium
in the maximum velocity of muscle shortening (~0.35 muscle lengths/s),
or in the rate constant of force redevelopment (Ktr, ~2.5 s1) after briefly
mechanically disrupting cross bridges with a rapid perturbation of muscle
length. Conclusions: Impaired contraction of border zone myocardium
involves a reduction in cross bridge formation, without effects on cross bridge
kinetics. Preliminary studies suggest proteolytic cleavage of contractile pro-
teins may play a role.
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Heart failure is characterized by a decrease in cardiac contractility and is a lead-
ing cause of morbidity and mortality. Treatment with cardiac glycosides such
as digitalis increases cardiac contractility by elevating intracellular calcium
through inhibition of the sodium-potassium ATPase (NKA). However, the ther-
apeutic window for this class of drugs is narrow as high calcium levels lead to
increased SR load, calcium leak, and cardiac arrhythmias. Alternatively, the
endogenous inhibitor of NKA, phospholemman (PLM), is dynamically regu-
lated. We hypothesize that a superinhibitory mutant of PLM will increase the
contractility of cardiac myocytes. This effect will be inherently self-limiting
since inhibition of NKA is relieved by phosphorylation or elevated intracellular
sodium. Here we used a high-throughput screen of PLM mutants utilizing fluo-
rescence microscopy to simultaneously measure PLM-NKA and PLM-PLM
binding. By tagging NKA with CFP and PLM with YFP, we can measure
NKA-PLM binding with heterotransfer FRET (CFP to YFP) and oligomeriza-
tion of PLM with homotransfer FRET (YFP to YFP). We observed that several
mutants have a decreased affinity for oligomerization (PLM-PLM binding)
leading to an increased apparent affinity for NKA. Future plans include creating
and screening many more mutants and measuring the functional effect of PLM-
based superinhibitors in vitro and in vivo.
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Ventricular fibrillation is one of the leading causes of death in the world.
Current therapy is based on a high-energy electric shock, which indiscrimin-
ately excites every cell in the muscle and may cause severe side effects such
as tissue damage and intolerable pain. The complex spatio-temporal dynamics
of fibrillation, induced by multiple interacting spiral waves, makes the design of
robust low-energy control strategies a challenging scientific problem.
Low-energy electric field stimuli lead to the formation of wave emitting sites at
structural heterogeneities in the tissue, with a density adjustable through field
strength. By applying a sequence of electric-field pulses, Low-Energy Anti-
Fibrillation pacing (LEAP) uses these wave sources to non-invasively control
the tissue from multiple sites and terminate fibrillation by progressive synchro-
nization. We present experiments on canine dogs, investigating the application of
LEAP to atrial (in-vitro and in-vivo) and ventricular fibrillation (in-vitro) as well
as the wave source recruitment mechanism in quiescent tissue [1]. We show that
the observed wave source density is in agreement with theoretical predictions
based on the size distribution of the cardiovascular tree. These findings are sup-
ported and extended by theoretical investigations revealing a general curvature-
dependent sensitivity of anatomical features to electric-field stimulation [2].
LEAP results in an energy reduction of 80% for the termination of fibrillation
compared to conventional defibrillation. Further energy reduction might be pos-
sible in specific scenarios by making use of negative-curvature structures on the
endocardium such as trabecular, papillary and pectinate muscles.
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